Stallergenes' allergy immunotherapy hits goal in phase 3

A phase 3 trial of Stallergenes Greer’s treatment for house dust mite-induced allergic rhinitis has met its primary endpoint. The late-phase success sets Stallergenes up to file for FDA approval of oral immunotherapy STAGR320.